Clinical TrialJun 25, 2026, 07:31 AM
Vivani Medical Gets Approval for Phase 1 Semaglutide Implant Trial
AI Summary
Vivani Medical, Inc. announced it has received approval from Bellberry, an Australian human research ethics committee, to initiate SLIM-1, a Phase 1 clinical trial for NPM-139, its semaglutide implant. The trial is expected to begin in mid-2026 and will assess the safety, tolerability, and pharmacokinetics of the miniature, ultra long-acting drug implant in obese or overweight subjects. The company is also preparing for SLIM-2, a subsequent efficacy-oriented trial, aiming to accelerate the development of NPM-139.
Key Highlights
- Vivani Medical received approval from Bellberry HREC in Australia to initiate the SLIM-1 clinical trial.
- SLIM-1 is a Phase 1 trial for NPM-139, a semaglutide implant, expected to start mid-2026.
- The trial will evaluate safety, tolerability, and pharmacokinetics of NPM-139 over four weeks.
- SLIM-1 is an open-label, randomized, active comparator-controlled trial with 10 subjects per group.
- The company is preparing for SLIM-2, a dose-ranging efficacy trial, pending SLIM-1 results.
Price Impact
More from VANI